TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer. (January 2023)

• Record Type: Journal Article
• Authors: Thomson, David J.; Cruickshank, Clare; Baines, Helen; Banner, Russell; Beasley, Matthew; Betts, Guy; Bulbeck, Helen; Charlwood, Frances; Christian, Judith; Clarke, Matthew; Donnelly, Olly; Foran, Bernadette; Gillies, Callum; Griffin, Clare; Homer, Jarrod J.; Langendijk, Johannes A.; Lee, Lip Wai; Lester, James; Lowe, Matthew; McPartlin, Andrew; Miles, Elizabeth; Nutting, Christopher; Palaniappan, Nachi; Prestwich, Robin; Price, James M.; Roberts, Clare; Roe, Justin; Shanmugasundaram, Ramkumar; Simões, Rita; Thompson, Anna; West, Catharine; Wilson, Lorna; Wolstenholme, Jane; Hall, Emma;
• Is Part Of: Clinical and translational radiation oncology. Volume 38(2023)
• Page Start: 147
• Page End: 154
• Publication Date: 2023-01
• Subjects: Cancer -- Radiotherapy -- Periodicals; Oncology -- Periodicals; Cancer -- Radiotherapy; Oncology; Radiation Oncology; Neoplasms -- radiotherapy; Translational Medical Research; Periodicals; Electronic journals; Periodicals; 616.9940642
• DOI: 10.1016/j.ctro.2022.11.010
• Languages: English
• ISSNs: 2405-6308

Abstract

Highlights: There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC). TORPEdO is the UK's first PBT clinical trial and aims to determine the benefits of PBT for OPSCC. Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning. There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will inform future studies in refining patient selection for IMPT.